FCRH5-Targeting and Other Emerging Bispecifics in R/R MM
Jeremy Larsen, MD, discusses data from a phase 1/2 study of cevostamab and other emerging bispecifics being evaluated in patients with relapsed/refractory multiple myeloma.
EP: 1.Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)
EP: 2.Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment
EP: 3.MonumenTAL-1: Evaluating the Anti- GPRC5D-Targetings Bispecific in R/R MM
Now Viewing
EP: 4.FCRH5-Targeting and Other Emerging Bispecifics in R/R MM
EP: 5.Incorporating Teclistamab in R/R MM: Insights from Clinical Practices Across the US
EP: 6.Step-up Dosing and Monitoring in Patients with MM on Bispecifics: Health System Perspectives
EP: 7.Best Practices for Transition of Care in Patients with MM on Teclistamab
EP: 8.Managing Infections and Other Toxicities Associated with Bispecifics in MM
EP: 9.Sequencing BCMA-Targeting Bispecifics in R/R MM Treatment
EP: 10.Choosing Between BCMA and Non-BCMA Bispecifics in Multiple Myeloma Treatment
EP: 11.Future Perspectives on the Role of Bispecifics in MM
EP: 12.Key Takeaways from Health Care Systems on the Role of Bispecifics in MM
EP: 13.Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma
EP: 14.Treatment Recommendations for Relapsed Multiple Myeloma
Recent Videos
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
